StreetInsider.com News Articles

PDS Biotech closes $11.3M PIPE led by Nant Capital, adds Soon-Shiong

Mon, 14 Sep 2026 10:30:19 -0400

PDS Biotechnology Corporation (Nasdaq: PDSB) completed the initial closing of a private investment in public equity (PIPE) transaction, raising approximately $11.3 million in gross proceeds, with the round led by Nant Capital, LLC.

The total PIPE is structured for up to $22.3 million, with a contingent milestone closing of up to $11 million that will be triggered upon the company's submission of a Phase 3 clinical trial protocol for its drug candidate PDS0301 to the FDA. At that milestone closing, Nant Capital and AB Group Ltd. would be obligated to invest $10 million and $1 million, respectively.

At the initial closing, the

PDS Biotech closes $11.3M PIPE led by Nant Capital, adds Soon-Shiong

Mon, 14 Sep 2026 10:30:19 -0400

At the initial closing, the

PDS Biotech closes $11.3M PIPE led by Nant Capital, adds Soon-Shiong

Mon, 14 Sep 2026 10:30:19 -0400

At the initial closing, the

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

Mon, 14 Sep 2026 10:30:00 -0400

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by Nant Capital, LLC (“Nant”) with additional participation by current investors. The PIPE also consists of a contingent milestone closing (the “Milestone Closing”) as described below.

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

Mon, 14 Sep 2026 10:30:00 -0400

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

Mon, 14 Sep 2026 10:30:00 -0400

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

Mon, 14 Sep 2026 10:30:00 -0400

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

Mon, 14 Sep 2026 10:30:00 -0400

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

Mon, 14 Sep 2026 10:30:00 -0400

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

NantHealth® Offers New NaviNet® AllPayer Subscription Packages, Now With Electronic Claim Submission